268 results on '"Sloop, Kyle W."'
Search Results
2. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
3. Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
4. Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances function of human islets
5. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
6. GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
7. GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice.
8. Structural insights into probe-dependent positive allosterism of the GLP-1 receptor
9. Activation of the GLP-1 receptor by a non-peptidic agonist
10. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
11. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology
12. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
13. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
14. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
15. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
16. 14-3-3-zeta mediates GLP-1 receptor agonist action to alter α cell proglucagon processing
17. GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
18. GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
19. The Furan Fatty Acid Metabolite CMPF Is Elevated in Diabetes and Induces β Cell Dysfunction
20. Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
21. Structural determinants of dual incretin receptor agonism by tirzepatide
22. Transcriptional Control of the Development and Function of the Hypothalamic-Pituitary Axis
23. Model of pediatric pituitary hormone deficiency separates the endocrine and neural functions of the LHX3 transcription factor in vivo
24. GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders
25. Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production
26. Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor
27. GLP-1 receptor signaling increases PCSK1 and β cell features in human α cells
28. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
29. Synthetic protease-activated class B GPCRs
30. Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
31. Severe short stature and endogenous growth hormone resistance in twin brothers without growth hormone gene mutations
32. Compound 18 Improves Glucose Tolerance in a Hepatocyte TGR5-dependent Manner in Mice
33. How May GIP Enhance the Therapeutic Efficacy of GLP-1?
34. The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition
35. Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
36. Erratum. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes 2019;68
37. Deficiency of Adiponectin Receptor 2 Reduces Diet-Induced Insulin Resistance but Promotes Type 2 Diabetes
38. Reduction of Hepatic Protein Tyrosine Phosphatase, Receptor, Type A (PTPRα) Expression Using an Antisense Oligonucleotide Improves Hyperglycemia, Steatosis and Plasma Triglycerides in Diabetic Mice: 1901-P
39. Reduction of Hepatic Glucagon Receptor Expression with an Optimized Antisense Oligonucleotide Increased Active GLP-1 Levels in Cynomolgus Monkeys without Pancreatic Alpha Cell Expansion or Hyperplasia: 1399-P
40. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides
41. Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism
42. Regulation of the Follicle-Stimulating Hormone β Gene by the LHX3 LIM-Homeodomain Transcription Factor
43. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
44. Molecular Analysis of LHX3 and PROP-1 in Pituitary Hormone Deficiency Patients with Posterior Pituitary Ectopia*
45. Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances function of human islets.
46. Differential Activation of Pituitary Hormone Genes by Human Lhx3 Isoforms with Distinct DNA Binding Properties
47. The current state of GPCR‐based drug discovery to treat metabolic disease
48. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
49. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
50. The Role of GLP-1 Receptor Expressed in Pancreatic a Cells in Regulating Glucagon Secretion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.